TCGA-39-5035-01A-01R-1443-07
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.530
- MYC_TARGETS_V1+0.500
- ALLOGRAFT_REJECTION+0.460
- OXIDATIVE_PHOSPHORYLATION+0.460
- E2F_TARGETS+0.440
- G2M_CHECKPOINT+0.370
- INTERFERON_GAMMA_RESPONSE+0.350
- INTERFERON_ALPHA_RESPONSE+0.300
- P53_PATHWAY+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.440
- HEDGEHOG_SIGNALING-0.400
- UV_RESPONSE_DN-0.310
- ANGIOGENESIS-0.250
- PROTEIN_SECRETION-0.240
- XENOBIOTIC_METABOLISM-0.150
- WNT_BETA_CATENIN_SIGNALING-0.140
- HEME_METABOLISM-0.130
- FATTY_ACID_METABOLISM-0.110
- NOTCH_SIGNALING-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-F7-A620-01A-11R-A28V-07 | — | — | 0.839 |
| 2 | TCGA-ZF-AA4V-01A-11R-A38B-07 | — | — | 0.809 |
| 3 | c63f3f74-14fa-4a9e-9925-30b0f5da7dd9 | — | — | 0.795 |
| 4 | TCGA-21-5787-01A-01R-1635-07 | — | cohortA4 | 0.790 |
| 5 | TCGA-D8-A1XL-01A-11R-A14M-07 | — | B | 0.786 |
| 6 | TCGA-52-7812-01A-11R-2125-07 | — | cohortA1 | 0.774 |
| 7 | MNG921 | — | — | 0.773 |
| 8 | SRR12475104 | — | — | 0.760 |
| 9 | TCGA-CQ-5327-01A-01R-1686-07 | — | — | 0.760 |
| 10 | TCGA-CV-5966-01A-11R-1686-07 | — | — | 0.760 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |